PP
AKBA icon

PrairieView Partners’s Akebia Therapeutics AKBA Stock Holding History

PrairieView Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,000
Closed -$4K – 356
2023
Q3 		$4K Hold
4,000
– – ﹤0.01% 322
2023
Q2 		$3K Buy
+4,000
New +$3.86K ﹤0.01% 380

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PrairieView Partners's AKBA Position: Q4 2023 in Review

PrairieView Partners sold out of Akebia Therapeutics (AKBA) in Q4 2023, closing a stake of 4,000 shares — an estimated $4K sold.

PrairieView Partners first reported a position in AKBA in Q2 2023 and held it in 2 quarters. The position peaked at $4K in Q3 2023. 87 funds tracked by Wall St. Rank hold AKBA as of Q4 2023.

  • PrairieView Partners reported no remaining Akebia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • PrairieView Partners sold 4,000 Akebia Therapeutics shares in Q4 2023, an estimated $4K.
  • PrairieView Partners first reported a position in Akebia Therapeutics in Q2 2023 and held it in 2 quarters.
  • PrairieView Partners's Akebia Therapeutics position peaked at $4K in Q3 2023.
  • 87 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2023.

Based on PrairieView Partners's 13F filing for Q4 2023, filed 26 Jan 2024.